NIH: APOE Genetics as a Major Determinant of Alzheimer’s Disease Pathobiology - SEPT 5-6

[aphorist]

https://www.nia.nih.gov/research/worksh ... s-20240822

APOE Genetics as a Major Determinant of Alzheimer’s Disease Pathobiology

Audience
Alzheimer's Disease and Related Dementia (AD/ADRD) physicians and biologists, and scientists interested in brain aging, neurodegenerative diseases, genetics, whole genome sequencing, global and local genetic ancestry analyses, single-cell genomic analyses, neurons-astrocytes-microglia interactions, and genetically driven therapeutic targets.

Dates
September 5, 2024 | 8:00 a.m. – 5:00 p.m. ET
September 6, 2024 | 8:00 a.m. – 3:00 p.m. ET

Location
This is a hybrid workshop. Participants can attend virtually via Zoom, or In Person on NIH Main Campus:

John Edwards Porter Neuroscience Research Center, Building 35
9000 Rockville Pike,
Bethesda, MD 20892

[NF52]

https://www.nia.nih.gov/research/worksh ... s-20240822

APOE Genetics as a Major Determinant of Alzheimer’s Disease Pathobiology

Audience
Alzheimer's Disease and Related Dementia (AD/ADRD) physicians and biologists, and scientists interested in brain aging, neurodegenerative diseases, genetics, whole genome sequencing, global and local genetic ancestry analyses, single-cell genomic analyses, neurons-astrocytes-microglia interactions, and genetically driven therapeutic targets.

Dates
September 5, 2024 | 8:00 a.m. – 5:00 p.m. ET
September 6, 2024 | 8:00 a.m. – 3:00 p.m. ET

Location
This is a hybrid workshop. Participants can attend virtually via Zoom, or In Person on NIH Main Campus:

John Edwards Porter Neuroscience Research Center, Building 35
9000 Rockville Pike,
Bethesda, MD 20892

Thanks for sharing this! I looked at the agenda, which offers many deep dives into ApoE4-related research . The audience is presumably mostly academic researchers, versus practicing clinicians or the lay public. The abridged agenda items below piqued my interest; others may want to check the link you attached.

Agenda. All times are in Eastern Daylight Time.
Day 1 | Thursday, September 5

8:30 a.m. Keynote Lecture, APOE4 as a toxic gain of function molecule, David M. Holtzman, M.D., Washington University

9:00 a.m. Session 1 | APOE genetics (Part 1)
The APOE4 Story: From Discovery to Diversity, Peggy Pericak-Vance, Ph.D., University of Miami
Local versus global ancestry in APOE: African and African American, Hispanic, and Asian populations, Farid Rajabli, Ph.D., University of Miami

10:35 a.m Session 1 | APOE genetics [last of 3 talks, so likely about 11:10 AM Eastern]
A Genetic Modifier of ε4/AD Association and APOE Expression, Lindsay Farrer, Ph.D., Boston University

1:15p.m. Session 2 | APOE genetics (Part 2 Continued)
APOE ε2 Allele and Protective Variants in APOE ε4/ε4 Carriers on Alzheimer’s Disease Risk, Gyungah Jun, Ph.D., Boston University
Rare Protective APOE Variants, Michael Greicius, M.D., MPH., Stanford University

1:55 p.m. Session 3 | Mechanisms of Disease-APOE
APOE-Genotype Dependent Single-Cell Transcriptomics of Alzheimer's Disease, Li Hui Tsai, Ph.D., Massachusetts Institute of Technology
The role of APOE genotype in microglial behavior and gene expression, Alison Goate, D.Phil., Mount Sinai
The role of APOE genetics in glial lipid metabolism and inflammation, Julia TCW, Ph.D., Boston University
The role of genetic variants and their influence on the immune response in myeloid cells/microglia, Christopher (Chris) Glass, M.D., Ph.D., University of California, San Diego

3:30 p.m. Session 3 | Mechanisms of Disease-APOE ) [2nd and 3rd talks; likely starting at 3:45 PM]
APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia, Michael Haney, Ph.D., University of Pennsylvania
Biology of APOE Protective Variants, Yadong Huang, M.D., Ph.D., Gladstone Institute/ University of California, San Francisco

Day 2 | Friday, September 6
8:00 am New technologies and moving towards therapeutics of APOE4 [2nd & 4th talks; starting around 8:15 & 9:30 ?]
APOE4 impact on vasculature Sally Temple, Ph.D., Neural Stem Cell Institute
Clinical trial of APOE2 gene therapy, Ronald Crystal, M.D., Weill Cornell Medical College

10:10 a.m. Session 4 (Continued)
Potential therapeutic role for peripheral APOE, Guojun Bu, Ph.D., Hong Kong University of Science and Technology
Antisense oligonucleotides for Alzheimer’s disease – a focus on APOE, Hien Zhao, Ph.D., Ionis Pharmaceuticals
Combination therapy in NACC and ADNI Alzheimer’s participants: Impact of APOE genotype and Sex, Francesca Vitali, Ph.D., University of Arizona
Using biomarkers in persons with different APOE variants to inform the study, treatment and prevention of AD, Eric Reiman, M.D., Banner Health
Therapeutic Correction of ApoE4-Mediated Endolysosomal Dysfunction in Alzheimer's Disease, Joachim Herz, M.D., University of Texas Southwestern Medical Center